| 249553 (Mage3) |
Vaccine |
GlaxoSmithKline |
II |
| 572016 |
ErbB-2 and EGFR dual kinase inhibitor |
GlaxoSmithKline |
III |
| ABI 007 (abraxane) |
Nanoparticle formulation of taxane |
American Partners |
II |
| ABT 510 |
Synthetic peptide |
Abbott |
II |
| ABT 751 |
Antimitotic sulfonamide |
Abbott |
II |
| ABX-EGF |
Anti-EGF monoclonal antibody |
Abgenix and Amgen |
II |
| Adenoviral p53 |
Adevixin Vaccine |
Intorgen |
II |
| AG3340 |
Metalloproteinase inhibitor |
Agouron |
III |
| Affinitak |
Antisense therapy |
Isis Pharmaceuticals Eli Lilly |
III |
| Alanosine |
Antimetabolite |
Triange |
II |
| AlimtaÒ(pemetrexed) |
Multi-targeted antifolate |
Eli Lilly |
Pending approval for 2nd line NSCLC |
| Aptosyn (exisulind) |
Selective apoptotic antineoplastic drug (SAAND) |
OSI Pharmaceuticals Aventis |
III |
| ASI 404 |
Antiangiogenesis |
Antisoma Roche |
II |
| Avastin (bevacizumab) |
Anti-VEGF |
Genentech |
III |
| BAY 43-9006 (sorafenib) |
MKI VEGFR-2, VEGFR-3, PDGFR-B, RAF, Kit, FLT-3, RET |
Bayer Pharmaceuticals Onyx Pharmaceuticals |
II |
| BB-10153 |
Thrombin activated plasminogen |
Vernalis Immunogen |
II |
| BLP-25 |
Vaccine |
Biomira |
II |
| BNP-1350 |
Topoisomerase 1 inhibitor |
Bio Neumerik |
II |
| BMS 248967 |
Bivalent ganglioside vaccine |
BMS |
I/II |
| CEA-Scan (arcitumomab) |
Radiolabeled antibody |
Immunomedics |
III |
| Cetuximab (Erbitux) |
MoAb EGFR |
BMS |
II |
| CI-1033 |
Erb-b2 and EGFR dual kinase inhibitor |
Pfizer |
II |
| CI-980 |
Mitotic inhibitor |
Pfizer |
I/II |
| CpG 7909 (Promune) |
Agaonist for TLR9 |
Coley Pfizer |
II |
| Dacogen (decitabine) |
DNA methyltransferase inhibitor |
MGI |
I |
| Dexosomes |
Immune modulator |
Anosys |
II |
| DN-101 (calcitriol) |
Analog of Vitamin D |
Novacia Aventis |
I |
| EKB-569 |
EGFR kinase inhibitor |
Wyeth |
II |
| EP-2101 |
Vaccine |
MGI |
I |
| Efaproxyn (efaxproxiva;) |
Radiosentsitizer |
Allos |
II |
| Flavopiridol |
Cyclin-dependent kinase inhibitor |
Aventis |
III |
| Gemzar (gemcitabine) |
Antimetabolite |
Eli Lilly |
III |
| Genasense (oblimersen) |
Antisense therapy |
Genta |
III |
| GL 331 |
Novel podophyllotoxin |
Genelabs |
II |
| GVAX Cancer Vaccine |
Vaccine |
Iomira Cell Genesys |
II |
| HTI-286 |
Synthetic analog of hemiasterlin antimtitotic |
Wyeth |
I |
| HUN901-DM1 |
huN901 antibody |
ImmunoGen |
II |
| Hycamtin (topotecan) |
Topoisomerase I inhibitor |
GlaxoSmithKline |
III |
| ILX-295501 |
Diarylsulfonamide |
ILEX |
II |
| INGN 225 |
P53 vaccine |
Introgen |
I |
| Iressa (gefitinib) |
EGFR tyrosine kinase inhibitor |
AstraZeneca |
Approved and phase III |
| ISIS 2503 |
antisense therapy |
ISIS Pharmaceuticals |
II |
| LEP-SN38 |
Liposomal encapsulated active metabolite of CPT-11 |
NeoPharm |
I |
| Liposomal cisplatin |
Platinum |
Johnson & Johnson |
II |
| Lung cancer vaccine |
Vaccine |
NovaRx |
II |
| Lurtotecan |
Topoisomerase inhibitor |
OSI Pharmaceuticals |
II |
| MAC-321 |
Taxane |
Wyeth |
II |
| MGI 114 |
ACYLFULVENE |
MGI |
I |
| Mitumomab |
Anti-idiotypic monoclonal antibody |
ImClone Systems |
III |
| MS-209 |
p-glycoptrotein inhibitor |
Berlex |
II |
| MS-275 |
Histone deacyltase inhibitor |
Berlex |
II |
| MVA-MUC1-IL2 |
Gene therapy |
Transgene |
II |
| Neotide |
Peptide |
Berlex |
I |
| Neovastat |
Anti-angiogenic |
Aeterna Laboratories |
III |
| Omnitarg (Pertuzumab) |
HER2-directed monoclonal antibody |
Genentech, Roche |
II |
| Onconase (ranpirnase) |
Ribonuclease anti-cancer drug |
Alfacell |
III (mesothelioma) |
| ONYX-015 |
Gene therapy |
Onyx Pharmaceuticals |
II |
| Orathecin (rubitecan) |
Topoisomerase I inhibitor |
SuperGen |
II |
| PDX (10-propargyl-10-deazaaminopterin) |
Antifolate |
Allos Therapeutics |
II |
| Pivanex (butyric acid) |
Histone deacetylase inhibitor |
Titan Pharmaceuticals |
II |
| Prothecan (Peg-camptothecin) |
Pegylated camptothecin |
Enzon |
II |
| Resmycin |
Doxorubicin Hcl inhalation |
Zivena |
II |
| RSR13 (efaproxiral) |
Allosteric hemoglobin radiosensitizer |
Allos Therapeutics |
II |
| SAI-EGF |
Anti EGFR Vaccine |
Cancer Vax |
I |
| Sarasar (lonafarnib) |
Oral Farnesyl Protein Transferase Inhibitor |
Schering-Plough |
III |
| SGN 15 |
Antibody-drug conjugate |
Seattle Genetics |
II |
| Squalamine |
Anti-angiogenic |
Genaera |
II |
| SR 48692 |
Neurotensin antagonist |
Sanofi-Synthelabo |
II |
| SS1-PE38 |
Anti-mesothelin immunotoxin |
Neopharm |
I Mesothelioma |
| Suramin |
Polysulphonated naphtylurea |
NCI |
I |
| T64 |
Antifolate |
Amgen |
II |
| Tarceva (erlotinib) |
EGF tyrosine kinase inhibitor |
Genentech, OSI Pharmaceuticals |
III |
| Targretin capsule (bexarotene) |
Retinoid |
Ligand Pharmaceuticals |
III |
| Tariquidar |
P-glycoprotein pump inhibitor |
QLT, Xenova Group |
III |
| Taxotere (docetaxel) |
Taxoid |
Aventis |
Approved and phase III |
| Tc-99m (depreotide injection) |
Synthetic linear tetrapeptide |
Berlex |
FDA submission |
| Telcyta (TLK286) |
Selective apoptotic agent |
Telik |
III |
| Thalomid (thalidomide) |
Immunomodulator |
Celgene |
III |
| Thymitaq (nolatrexed) |
Thymidylate synthase inhibitor |
Eximias Pharmaceutical |
II |
| Tirapazamine |
Bioreductive agent |
Sanofi-Synthelabo |
III |
| Velcade (bortezomib) |
Proteosome inhibitor |
Millenium |
II |
| Xyotax (polyglutamate paclitaxel) |
Taxane |
Cell Therapeutics |
III |
| Yondelis (trabectedin) |
Tetrahydrosoquinalonne |
Pharma Mar Ortho Biotech |
II |
Patient Home
Meeting Calendar
